Aldeyra Therapeutics Achieves Goals In Crossover Clinical Trial Of 0.25% Reproxalap Solution
(RTTNews) - Aldeyra Therapeutics, Inc. (ALDX) announced Tuesday the achievement of the primary endpoints in a sequence-randomized, double-masked, vehicle-controlled crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease.
Reproxalap was statistically superior to vehicle for each of the two prespecified primary endpoints, ocular redness in a dry eye chamber and Schirmer test, a measure of tear production, after a single day of dosing.
The secondary endpoint of Schirmer test =10 mm responder analysis, which was multiplicity-controlled, was also achieved.
A pre-NDA meeting with the FDA has been scheduled for the third quarter of 2022.
For More Such Health News, visit rttnews.com
Aldeyra Therapeutics Gets CRL From FDA For NDA Of ADX-2191 To Treat Primary Vitreoretinal Lymphoma
U.S. Consumer Prices Increase In Line With Estimates In August
IEA Cuts Oil Demand Forecast; Canadian Markets Eye Recovery
Canadian Dollar Falls As Oil Prices Edge Lower
Kroger Q2 Profit Rises, Backs FY26 Adj. Earnings View, Cuts Sales Growth Forecast; Stock Drops
UK Stocks Rise On GDP Growth, Oil Price Decline
French Stocks Rise On Oil Price Drop, Middle East Concerns Persist
